Navigation Links
Celsion Corporation Provides Business Update
Date:4/23/2013

LAWRENCEVILLE, N.J., April 23, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today is providing a business update, including the latest findings from its analysis of clinical trial results for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.  Celsion is evaluating ThermoDox® in a Phase III clinical trial for primary liver cancer (the HEAT Study), a Phase II clinical trial for colorectal liver metastasis and a Phase II clinical trial for recurrent chest wall breast cancer.

Phase III HEAT Study Data Analysis 

The Company has conducted a comprehensive analysis of the data from the Phase III HEAT Study with key principal investigators, data experts and liver cancer experts.  This follows the announcement on January 31, 2013, that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the study's primary endpoint.  Emerging data from the HEAT Study post analysis demonstrates that ThermoDox® markedly improves progression free survival (PFS) and overall survival (OS) in patients who had optimal RFA.  The analysis indicates that if patients' lesions undergo RFA for 45 minutes or more, they clearly benefitted from ThermoDox®.  These findings apply to HCC lesions from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a sizable subgroup of patients.  This data is subject to further verification and review by the HEAT Study Steering Committee. 

"We have completed a thorough review of the HEAT Study and there is clear evidence that ThermoDox® can benefit patients when RFA is optimized," said Dr. Nicholas Borys , Celsion's Vice President and Chief Medical Officer.  "These data are very exciting and consistent with the mechanism of ThermoDox&
'/>"/>

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celsion Corporation Announces $15 Million Registered Direct Offering
2. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
3. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
4. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
5. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
6. Neogen Corporation Announces 2nd Quarter Results Conference Call
7. Luminex Corporation to Present at JP Morgan Healthcare Conference
8. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
9. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
10. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
11. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ... solutions, today announced that Lupin Limited, one of ... of Freeslate’s CM Protégé PharmD System ... Lupin, headquartered in Mumbai, India, is focused on ... branded formulations and Active Pharmaceutical Ingredients (APIs) for ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... developing solutions based on the products of cells ... they have entered into an international license agreement ... containing Histogen’s proprietary multipotent cell conditioned media (CCM). ... to the existing license between Histogen and Suneva ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... are joining together with two institutes from the ... develop more reliable tools for bringing safer, more ... Organovo is collaborating with the National Center for ... Institute (NEI) to develop better and more clinically ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, ... management ( SCM ) and sales and operations planning ... gold sponsor of the Biomanufacturing Summit , which ... January 30 – 31, 2014.  At the conference, join ... Chain at Amgen, as she presents ,Supply Chain: Improving ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Scientific,Corporation (NYSE: BSX ) is scheduled to participate ... being held September 10 and 11,in New York City. ... make a,25-minute presentation followed by a 25-minute question and ... a.m. ET. A live webcast of Mr. LaViolette,s ...
... Artery ... Disease - ... -, FREMONT, Calif., Aug. 28 Vermillion, Inc.,(Nasdaq: VRML ), formerly ... called beta-2,microglobulin may aid in the diagnosis of peripheral artery disease (PAD).,The findings, ...
... (Pink Sheets: BIEL), announced today that Astonix Life,Science, ... provide ActiPatch,Therapy to the healthcare market in Singapore. ... ActiPatch to the market has been warmly,received. ... the Healthcare providers,in Singapore has been strong enough ...
Cached Biology Technology:Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease 2Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease 3BioElectronics Corporation Announces Singapore and Malaysia Sales 2
(Date:4/14/2014)... of subarctic forest moths in Finnish Lapland suggests that ... on animals and plants because much of the harm ... of 80 moth species and found that 90 percent ... study period, from 1978 to 2009. During that time, ... degrees Fahrenheit, and winter precipitation increased as well. , ...
(Date:4/14/2014)... climate over the past three decades have caused small ... national animal. UCLA biologists have found that not only ... has also become shorter and higher pitched. ... integrative biology and physiology and of ecology and evolutionary ... study examined 170 male coqui frogs ( Eleutherodactylus coqui ...
(Date:4/14/2014)... ( http://www.ucr.edu ) David Kisailus, the Winston ... University of California, Riverside,s Bourns College of Engineering, ... Fellows are young scientists selected by the advisory ... National Academy of Sciences and organizers of the ... series. The Kavli Foundation, which is based in ...
Breaking Biology News(10 mins):Moth study suggests hidden climate change impacts 2Moth study suggests hidden climate change impacts 3Climate change a likely culprit in coqui frog's altered calls, say UCLA biologists 2Professor receives young scientist honor 2
... permanently damaged their skin cells, causing them to overproduce ... uneven skin tone over time. But new research indicates ... arthritis ?can actually help stop the formation of new ... findings on glucosamine may impact the way dermatologists treat ...
... warm, sun-drenched, tropical seas; some species are found at ... waters throughout the world's oceans. Some cold-water coral reefs ... a diversity rivaling some better known tropical coral reefs. ... method in which vessels drag large, heavily weighted nets ...
... the rewarding effect of cocaine on mice by genetically ... animal's brain. , While the researchers aren't suggesting that ... brings to light the key protein that controls cocaine's ... medications that achieve the same results and therefore help ...
Cached Biology News:Science finds new fix for UV-damaged skin in arthritis treatment 2Science finds new fix for UV-damaged skin in arthritis treatment 3Ocean acidification threatens cold-water coral ecosystems 2Genetically altered mice no longer like cocaine 2Genetically altered mice no longer like cocaine 3
Human Apolipoprotein B100 Affinity Purified Polyclonal Ab ENTREZ GeneID: 338...
hypertension-related calcium-regulated gene, mRNA...
Human PLUNC MAb (Clone 252512)...
... GRASP1 ( Abpromise for all ... Synthetic peptide corresponding to amino ... region of rat GRASP1, conjugated to ... Entrez GeneID: 56850 ...
Biology Products: